Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Cancer. 2015 Jul 15;121(21):3853–3861. doi: 10.1002/cncr.29578

Figure 3. Clinical evidence of relief of feedback inhibition on AR in response to mTOR inhibition.

Figure 3

AR: androgen receptor, PSA: prostate-specific antigen.

Change from baseline PSA level for 13 patients on study who experienced a rise in PSA on treatment and then a PSA decline following discontinuation of treatment. Week 0 indicates discontinuation of treatment. Two patients (orange lines) were on treatment ≥ 20 weeks; 4 patients (green lines) were on treatment for 12 weeks; 3 patients (blue lines) were on treatment for 8-10 weeks (graphed as 8 weeks); and 4 patients (red lines) were on treatment for 2−6 weeks (graphed as 4 weeks). Black lines show the average percent change in PSA from baseline at each time point along with a corresponding 95% confidence interval.